Discovering ALDH1A2: A Promising Drug Target and Biomarker (G8854)

Target Name: ALDH1A2

NCBI ID: G8854

ALDH1A2

Discovering ALDH1A2: A Promising Drug Target and Biomarker

ALDH1A2 (also known as RALDH 2) is a gene that encodes a protein known as the small subunit of the NAD+-dependent alkaline phosphatase enzyme. This enzyme plays a crucial role in the regulation of various cellular processes, including metabolism, cell signaling, and inflammation.

Recent studies have identified ALDH1A2 as a potential drug target for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. This is because the enzyme is involved in the metabolism of a variety of molecules, including drugs that are used to treat these conditions. For example, ALDH1A2 is involved in the metabolism of chemotherapy drugs, which can lead to reduced efficacy or increased toxicity.

In addition, ALDH1A2 has also been identified as a potential biomarker for certain diseases. For example, altered levels of ALDH1A2 have been observed in the brains of individuals with Alzheimer's disease, which is a neurodegenerative disorder. Additionally, ALDH1A2 has been shown to be altered in the blood samples of individuals with certain autoimmune disorders, such as rheumatoid arthritis and multiple sclerosis.

The discovery and characterization of ALDH1A2 as a potential drug target and biomarker has important implications for the development of new treatments for a variety of diseases. By targeting this enzyme, researchers may be able to develop drugs that can inhibit its activity and treat diseases that are currently incurable or treated with limited success. Additionally, the characterization of ALDH1A2 as a potential biomarker may have implications for the development of diagnostic tests for these diseases.

In conclusion, ALDH1A2 is a promising drug target and biomarker that has the potential to revolutionize the treatment of a variety of diseases. Further research is needed to fully understand its role and to develop effective treatments.

Protein Name: Aldehyde Dehydrogenase 1 Family Member A2

Functions: Converts retinaldehyde to retinoic acid (PubMed:29240402, PubMed:33565183). Recognizes as substrates free retinal and cellular retinol-binding protein-bound retinal. Can metabolize octanal and decanal, but has only very low activity with benzaldehyde, acetaldehyde and propanal. Displays complete lack of activity with citral (By similarity)

The "ALDH1A2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ALDH1A2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets